Skip to search formSkip to main contentSkip to account menu

Pseudobulbar affect

National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2016
2016
Therapeutic Approach of a High Functioning Individual With Traumatic Brain Injury and Subsequent Emotional Volatility With Features of Pathological Laughter and Crying With Dextromethorphan/Quinidine
AbstractPathological laughing and crying, or pseudobulbar affect (PBA), has been described in patients with neurological… 
2016
2016
Pharmacologic Management Strategies in ALS #301.
The combination drug dextromethorphan/quinidine is the only FDA-approved treatment of pseudobulbar affect (PBA). Its mechanism of… 
2016
2016
An Open-Label Study to Assess Safety, Tolerability, and Effectiveness of Dextromethorphan/Quinidine for Pseudobulbar Affect (PBA) in Dementia, Stroke and Traumatic Brain Injury: PRISM II Combined…
2016
2016
Pseudobulbar Affect (PBA) as a Predictor of Survival in ALS (P5.089)
Objective: To determine if the early presence of PBA is a predictor of ALS prognosis in a population-based ALS incident cohort… 
2015
2015
Dextromethorphan/quinidine for treatment of pseudobulbar affect (PBA) in patients with dementia: Examination of cns-ls outcomes in a 12-week open-label trial (PRISM II)
2015
2015
Persistent pseudobulbar affect secondary to acute disseminated encephalomyelitis
Pseudobulbar affect (PBA) is a common complication of central nervous system diseases such as stroke, multiple sclerosis, and… 
2015
2015
A frontal syndrome due to a brainstem lesion
Review
2014
Review
2014
Study Of Pseudobulbar Affect Symptoms In Veterans With Mild Traumatic Brain (P5.341)
OBJECTIVE: Characterize and estimate the prevalence of pseudobulbar affect (PBA) symptoms in a sample of OEF/OIF/OND veterans… 
2013
2013
Clinical, behavioral, and treatment differences in nursing facility residents with dementia, with and without pseudobulbar affect symptomatology.
OBJECTIVES Characterize the prevalence and impact of crying and tearfulness as symptoms that may be suggestive of pseudobulbar… 
2010
2010
Market watch: Upcoming market catalysts in Q4 2010
Several important US Food and Drug Administration (FDA) approval decisions are expected in the fourth quarter of 2010. First, the… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)